Phase 3 trial
Anaptys reports positive results for its rare skin disease drug and seeks a partner for commercialization
Anika Sharma
AnaptysBio has unveiled promising phase 3 data for its rare skin disease drug candidate, indicating a potential challenge to Boehringer ...
Adlai revives Novartisâ abandoned cancer drug, raises $57.5M in IPO to fund phase 3 trial
Anika Sharma
Adlai Nortye has solidified its financial footing, paving the way to determine the fate of its strategic investment in an ...
Astellas claims positive results for Izervay in geographic atrophy but remains vague on data
Anika Sharma
Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...
Acelyrinâs lead drug flops in phase 3 trial, wiping out half of its market value
Anika Sharma
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...
BioCardiaâs cell therapy fails to improve heart failure outcomes in Phase 3 trial
Anika Sharma
BioCardia’s attempts to revive its paused phase 3 heart failure trial have hit a major setback, as results fail to ...
